

PRESS RELEASE

Number 27

WACKER Will Not Produce an mRNA Vaccine for CureVac

Munich, September 14, 2021 – CureVac N.V., a company based in Tübingen, Germany, needs less production capacity for CVnCOV, its mRNA vaccine candidate against Covid-19. As a result, it has terminated its contract with Wacker Chemie AG.

This will not have any significant impact on WACKER BIOSOLUTIONS' sales and earnings in 2021. "And it does not change our medium-term targets for the Biosolutions division either," said Dr. Susanne Leonhartsberger, the division's head. "We are confident that we can provide other customers with the freed-up capacity for their mRNA and other molecules in the future," added Leonhartsberger. WACKER's site in Amsterdam has manufactured vaccines for customers for more than 20 years.

For further information, please contact:

Wacker Chemie AG
Media Relations & Information
Jörg Hettmann
Tel. +49 89 6279-1508
joerg.hettmann@wacker.com
www.wacker.com
follow us on:   

The company in brief:

WACKER is a global chemical company with some 14,300 employees and annual sales of around € 4.69 billion (2020).
WACKER has a global network of 26 production sites, 23 technical competence centers and 52 sales offices.

WACKER SILICONES

Silicone fluids, emulsions, rubber grades and resins; silanes; pyrogenic silicas; thermoplastic silicone elastomers

WACKER POLYMERS

Polyvinyl acetates and vinyl acetate copolymers and terpolymers in the form of dispersible polymer powders, dispersions, solid resins and solutions

WACKER BIOSOLUTIONS

Biotech products such as cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins

WACKER POLYSILICON

Polysilicon for the semiconductor and photovoltaic industries